Genomatica Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Genomatica's estimated revenue is currently $33.2M per year.
- Genomatica received $90.0M in venture funding in October 2018.
- Genomatica's estimated revenue per employee is $196331
- Genomatica's total funding is $191.1M.
- Genomatica has 169 Employees.
- Genomatica grew their employee count by 25% last year.
- Genomatica currently has 5 job openings.
|Damien Perriman||Senior Vice President, Specialty Chemicals|
|Nelson Barton||VP Research/Development|
|Tae Yang||Director of Systems Bioengineering|
|Priti Pharkya||Senior Director, Strategy and Corporate Development|
|Joe Kuterbach||VP Operations and Technology Transfer|
|Lisa Kennedy||Director Business Development|
|Michael Japs||Senior Director, Process Technology|
|Bill Baum||Executive Chairman and Chief Business Development Officer|
|Benjamin Griffin||Program Director and Director, Enzyme Engineering|
|Itzel Ramos-Solis||Director, Strain Engineering|
What Is Genomatica?
Genomatica is a widely-recognized technology leader for the chemical industry. We develop manufacturing processes that enable our licensee partners to produce the world's most widely-used chemicals a better way, from alternative feedstocks, with better economics and greater sustainability than petroleum-based processes. Genomatica has delivered the industry's first commercial biobased process for a high-volume intermediate chemical. Our GENO BDO process has produced thousands of tons of BDO and been licensed by BASF and Novamont. Multiple large chemical firms have publicly validated quality or described commercialization plans, including Invista (for its well-known Lycra® spandex), DSM, Lanxess, Toray, and Far Eastern New Century. Our biotechnology platform and over 500 patents and applications enable us to develop processes for additional major chemicals. The next is for butadiene, with Versalis and Braskem as partners, and over $100 million in industry support. We have also announced our program for nylon intermediates, including HMD, caprolactam and adipic acid. We've been honored to receive extensive recognition for our innovation, commercialization track record, and potential for broad impact. Recent examples include the Kirkpatrick Award, for the most noteworthy chemical engineering technology commercialized in the world, and the 2015 World Economic Forum Technology Pioneer award. See current job openings at www.genomatica.com/about/careers.keywords:Biotechnology,Cleantech,Energy,Food & Beverages,Healthcare,Pharmaceuticals,Solar Power,Wind Power
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Canadian Solar ...||$217.6M||1109||3%|
|San Diego Count...||$11.3M||58||12%|
Genomatica, which uses bacteria to manufacture chemicals from plants, announced Thursday that it is acquiring assets from the REG Life ...
Adds capabilities to meet increasing demand for sustainable products. SAN DIEGO, June 06, 2019 (GLOBE NEWSWIRE) -- Genomatica, ...
“We are pleased to be selling our Life Sciences' assets to Genomatica, who are well positioned to build upon the technical progress we have ...
|2000-03-02||$45.0M||Undisclosed||VantagePoint Venture Partners||Article|
|2011-03-02||$45.0M||Undisclosed||VantagePoint Venture Partners||Article|
Genomatica Executive Hires
|2010-09-14||Bill Baum||Chairman/Chief Business Development Of||Article|
|2011-07-19||Michael E. Keane||EVP/CFO||Article|
|2012-05-01||Jeff Lievense||EVP Process Technology||Article|